Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression
C Rosso, Ioannis A. Voutsadakis
Clinical Breast Cancer (2022) Vol. 22, Iss. 4, pp. 391-397
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
Chiara Molinelli, Flavia Jacobs, Elisa Agostinetto, et al.
ESMO Open (2023) Vol. 8, Iss. 4, pp. 101592-101592
Open Access | Times Cited: 43
Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
Huina Zhang, Yan Peng
Cancers (2022) Vol. 15, Iss. 1, pp. 126-126
Open Access | Times Cited: 45
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
Lei-Jie Dai, Ding Ma, Yu-Zheng Xu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort
Ximena Baez‐Navarro, Mieke Van Bockstal, Eleni‐Rosalina Andrinopoulou, et al.
Modern Pathology (2023) Vol. 36, Iss. 4, pp. 100087-100087
Closed Access | Times Cited: 22
Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
Shuling Zhou, Ting Liu, Xiaying Kuang, et al.
The Breast (2022) Vol. 67, pp. 1-7
Open Access | Times Cited: 32
HER2-low breast cancers: Current insights and future directions
Huina Zhang, Cansu Karakaş, Haley Tyburski, et al.
Seminars in Diagnostic Pathology (2022) Vol. 39, Iss. 5, pp. 305-312
Closed Access | Times Cited: 29
Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
Katrin Almstedt, Lisa Krauthauser, Franziska Kappenberg, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1413-1413
Open Access | Times Cited: 19
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
Giuseppe Curigliano, Rebecca Dent, H. Earle, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102989-102989
Open Access | Times Cited: 6
Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients
Ciqiu Yang, Xiaoqi Zhang, Yitian Chen, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 185, pp. 103962-103962
Closed Access | Times Cited: 14
HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC
Jing-Jing Li, Yue Yu, Jie Ge
Breast Cancer (2023) Vol. 30, Iss. 3, pp. 364-378
Closed Access | Times Cited: 13
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Lin-Yu Xia, Xuchen Cao, Yue Yu
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Prognostic implications of HER2NEU‐low in metastatic breast cancer
Zachary Neubauer, Shaakir Hasan, Robert H. Press, et al.
Cancer Medicine (2024) Vol. 13, Iss. 2
Open Access | Times Cited: 4
From Text to Insight: A Natural Language Processing-Based Analysis of Burst and Research Trends in HER2-low Breast Cancer Patients
Muyao Li, Ang Zheng, Mingjie Song, et al.
Ageing Research Reviews (2025) Vol. 106, pp. 102692-102692
Open Access
Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis
Tong Wei, Dingyuan Wang, Songlin Gao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study
Fereshteh Abbasvandi, Mahdis Bayat, Atieh Akbari, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
N Atallah, Maria Haque, Cecily Quinn, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113371-113371
Open Access | Times Cited: 9
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
Heng-Zhou Lai, Jierong Han, Xi Fu, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3774-3774
Open Access | Times Cited: 14
Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center
Yan Hu, Dan Jones, Weiqiang Zhao, et al.
Modern Pathology (2023) Vol. 36, Iss. 7, pp. 100164-100164
Closed Access | Times Cited: 8
Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study
Libo Yang, Yuqiong Liu, Dandan Han, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 9, pp. 5653-5662
Closed Access | Times Cited: 8
Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer
Tong Wei, Yi‐Kun Kang, Xue Wang, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 7, pp. 550-558
Open Access | Times Cited: 2
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 3-4, pp. 117-135
Closed Access | Times Cited: 2
The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer
Woong Ki Park, Seok Jin Nam, Seok Won Kim, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2566-2566
Open Access | Times Cited: 2
Understanding the Spectrum of HER2 Status in Breast Cancer: From HER2-Positive to Ultra-Low HER2
Sana Ahuja, Adil Aziz Khan, Sufian Zaheer
Pathology - Research and Practice (2024) Vol. 262, pp. 155550-155550
Closed Access | Times Cited: 2
Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
Lin-Yu Xia, Xuchen Cao, Qing-Lin Hu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis
Fausto Petrelli, Carmen G. Rea, Maria Chiara Parati, et al.
Anticancer Research (2023) Vol. 43, Iss. 10, pp. 4303-4313
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top